nach oben

BioDrugs

Erschienen in:

01.03.2007 | Adis Profile Report

Panitumumab in the Treatment of Metastatic Colorectal Cancer

Profile Report

verfasst von: Sheridan M. Hoy, Antona J. Wagstaff

Erschienen in: BioDrugs | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Excerpt

Approximately 655 000 deaths worldwide each year can be attributed to colorectal cancer.[4] The primary treatment option for patients with colorectal cancer is surgery;[5] however, approximately 50% of patients will subsequently develop metastases.[6,7] The prognosis for these patients is generally poor; median survival from diagnosis is 6–9 months[8] and the 5-year survival rate is <5%.[6] Nevertheless, quality of life, time to disease progression, and overall survival in patients with metastatic colorectal cancer can be improved with the use of chemotherapy.[6,7] …

The use of trade names is for product identification purposes only and does not imply endorsement.

Hoy SM, Wagstaff AJ. Panitumumab: in the treatment of metastatic colorectal cancer. Drugs 2006; 66(15): 2005–14PubMedCrossRef

Malik I. Panitumumab: a viewpoint by Imtiaz Malik. Drugs 2006; 66(15): 2015CrossRef

Ranson M. Panitumumab: a viewpoint by Malcolm Ranson. Drugs 2006; 66(15): 2015–6CrossRef

World Health Organization. Cancer [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs297/en/print.html [Accessed 2006 May 18]

Labianca RF, Beretta GD, Pessi MA. Colorectal cancer: disease management considerations. Drugs 2001; 61(12): 1751–64PubMedCrossRef

Jefford M, Zalcberg J. Recent advances in the systemic therapy of metastatic colorectal cancer. Am J Cancer 2005; 4(1): 15–34CrossRef

Coutinho AK, Rocha Lima CMS. Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Control 2003; 10(3): 224–38PubMed

Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000 Sep 2; 321(7260): 531–5PubMedCrossRef

Alekshun T, Garrett C. Targeted therapies in the treatment of colorectal cancers. Cancer Control 2005 Apr; 12(2): 105–10PubMed

10.

Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 2005; 103(12): 2435–46PubMedCrossRef

11.

McWilliams RR, Erlichman C. Novel therapeutics in colorectal cancer. Dis Colon Rectum 2005; 48(8): 1632–50PubMedCrossRef

12.

Ranson M. Technology evaluation: ABX-EGF, Abgenix/Amgen. Curr Opin Mol Ther 2003 Oct; 5(5): 541–6PubMed

13.

Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004 Dec; 11(4): 689–708PubMedCrossRef

14.

Veronese ML, O’Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004 Jun; 40(9): 1292–301PubMedCrossRef

15.

Levene AP, Singh G, Palmieri C. Therapeutic monoclonal antibodies in oncology. J R Soc Med 2005; 98(4): 146–52PubMedCrossRef

16.

Yang X-D, Jia X-C, Corvalan JRF, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17–23PubMedCrossRef

17.

Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006 Jan-Feb; 29(1): 1–9PubMedCrossRef

18.

Peeters M, Van Custem E, Siena S, et al. A phase III, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) versus BSC alone in patients with metastatic colorectal cancer [abstract no. CP-1] plus oral presentation at 97th Annual Meeting of the American Association for Cancer Research; 2006 Apr 1-5; Washington, DC

19.

Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥10% epidermal growth factor receptor (EGFr) [abstract no. 3548]. J Clin Oncol 2006; 24 (18 Suppl. Pt 1): 158s. Plus poster presented at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting; 2006 Jun 2–6; Atlanta (GA)

20.

Hecht J, Mitchell E, Baranda J, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (<l–9%) or negative (<1 %) levels of epidermal growth factor receptor (EGFr) [abstract no. 3547]. J Clin Oncol 2006; 24 (18 Suppl. Pt 1): 157s. Plus poster presented at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting; 2006 Jun 2–6; Atlanta (GA)CrossRef

21.

Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer [abstract no. 3520]. J Clin Oncol 2005; 23 (16 Suppl. Pt I): 251S. Plus poster presented at the 41st American Society of Clinical Oncology (ASCO) Annual Meeting; 2005 May 13–17; Orlando (FL)

22.

Hecht J, Posey S, Tchekmedyian S, et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan or FOLFIRI for first-line treatment of metastatic colorectal cancer [abstract no. 237]. 3rd Annual Gastrointestinal Cancers Symposium; 2006 Jan 26–28; San Francisco (CA)

23.

Amgen. Vectibix™ [panitumumab] prescribing information [online]. Available from URL: http://www.fda.gov/ [Accessed 2006 Oct 3]

Titel: Panitumumab in the Treatment of Metastatic Colorectal Cancer
Profile Report
verfasst von: Sheridan M. Hoy
Antona J. Wagstaff
Publikationsdatum: 01.03.2007
Verlag: Springer International Publishing
Erschienen in: BioDrugs / Ausgabe 2/2007
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI: https://doi.org/10.2165/00063030-200721020-00011

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Panitumumab in the Treatment of Metastatic Colorectal Cancer

Profile Report

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Adalimumab in Crohn’s Disease

Immunoglobulin Treatment for Primary Antibody Deficiencies

Ethics and Embryonic Stem Cell Research

HER-2-Positive Breast Cancer

Targeting the Phosphatidylinositol 3-Kinase Pathway in Airway Smooth Muscle

Adalimumab in Crohn’s Disease